4-chloro-N-(3-chloro-4-hydroxynaphthalen-1-yl)benzenesulfonamide | 139719-07-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 4-chloro-N-(3-chloro-4-hydroxynaphthalen-1-yl)benzenesulfonamide
• CAS: 139719-07-6
• 化学式: C₁₆H₁₁Cl₂NO₃S
• 分子量: 368.24
• InChiKey: ADDAZRPOZJHNIE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.3
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  74.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-chloro-N-(3-chloro-4-hydroxynaphthalen-1-yl)benzenesulfonamide 在 lead(IV) acetate 作用下， 以 溶剂黄146 为溶剂， 反应 0.33h， 以76.5%的产率得到4-chloro-N-(3-chloro-4-oxonaphthalen-1(4H)-ylidene)benzenesulfonamide
  参考文献：
  名称：

  Avdeenko, A. P.; Velichko, N. V.; Romanenko, E. A., Journal of Organic Chemistry USSR (English Translation), 1991, vol. 27, # 8, p. 1535 - 1543

  摘要：

  DOI：
• 作为产物：
  描述：

  4-氨基-1-萘酚 在 lead(IV) acetate 、 盐酸 、 碳酸氢钠 作用下， 以 氯仿 、 水 、 溶剂黄146 为溶剂， 反应 1.0h， 生成 4-chloro-N-(3-chloro-4-hydroxynaphthalen-1-yl)benzenesulfonamide
  参考文献：
  名称：

  Avdeenko, A. P.; Velichko, N. V.; Romanenko, E. A., Journal of Organic Chemistry USSR (English Translation), 1991, vol. 27, # 8, p. 1535 - 1543

  摘要：

  DOI：

文献信息

• Methods and compositions for treatment of muscle wasting, muscle weakness, and/or cachexia
  申请人：Baylor College of Medicine

  公开号：US10676455B2

  公开（公告）日：2020-06-09

  Embodiments of the invention include methods of treating, preventing, and/or reduce the risk or severity of a condition selected from the group consisting of muscle wasting, muscle weakness, cachexia, and a combination thereof in an individual in need thereof. In some embodiments, particular small molecules are employed for treatment, prevention, and/or reduction in the risk of muscle wasting. In at least particular cases, the small molecules are inhibitors of STAT3.

  本发明的实施方案包括治疗、预防和/或降低有需要的个体发生选自肌肉萎缩、肌无力、恶病质及其组合的疾病的风险或严重程度的方法。在某些实施方案中，采用特定的小分子来治疗、预防和/或降低肌肉萎缩的风险。至少在特定情况下，小分子是 STAT3 的抑制剂。
• STAT3 INHIBITORS
  申请人：Tweardy David J.

  公开号：US20100041685A1

  公开（公告）日：2010-02-18

  Small molecule inhibitors of Stat3 and their derivatives are disclosed. Also described are methods to inhibit cell growth by use of Stat3 inhibitors, and the use of Stat3 inhibitors for the prevention and/or treatment of cancer. Further, inhibitors of Stat3 that also do not inhibit Stat1 are described as well as their derivatives. Methods of screening additional compounds for Stat3 inhibition activity and/or non-inhibition of Stat1 activity are also described herein.
• STAT3 Inhibitors
  申请人：Baylor College of Medicine

  公开号：US20140296270A1

  公开（公告）日：2014-10-02

  Small molecule inhibitors of Stat3 and their derivatives are disclosed. Also described are methods to inhibit cell growth by use of Stat3 inhibitors, and the use of Stat3 inhibitors for the prevention and/or treatment of cancer. Further, inhibitors of Stat3 that also do not inhibit Stat1 are described as well as their derivatives. Methods of screening additional compounds for Stat3 inhibition activity and/or non-inhibition of Stat1 activity are also described herein.
• METHODS AND COMPOSITIONS FOR PREVENTION OF ALLERGIC REACTION
  申请人：Baylor College of Medicine

  公开号：US20150031714A1

  公开（公告）日：2015-01-29

  Embodiments of the invention include methods of preventing and/or reducing the risk or severity of an allergic reaction in an individual. In some embodiments, particular small molecules are employed for prevention and/or reduction in the risk or severity of anaphylaxis. In at least particular cases, the small molecules are inhibitors of STAT3. In some cases, the small molecule comprises N-(1′,2-dihydroxy-1,2′-binaphthalen-4′-yl)-4-methoxybenzenesulfonamide.
• METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCLE WASTING, MUSCLE WEAKNESS, AND/OR CACHEXIA
  申请人：BAYLOR COLLEGE OF MEDICINE

  公开号：US20150024032A1

  公开（公告）日：2015-01-22

  Embodiments of the invention include methods of treating, preventing, and/or reduce the risk or severity of a condition selected from the group consisting of muscle wasting, muscle weakness, cachexia, and a combination thereof in an individual in need thereof. In some embodiments, particular small molecules are employed for treatment, prevention, and/or reduction in the risk of muscle wasting. In at least particular cases, the small molecules are inhibitors of STAT3.